BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19903788)

  • 1. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
    Sredni ST; Gadd S; Huang CC; Breslow N; Grundy P; Green DM; Dome JS; Shamberger RC; Beckwith JB; Perlman EJ;
    Clin Cancer Res; 2009 Nov; 15(22):6800-9. PubMed ID: 19903788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.
    Perlman EJ; Grundy PE; Anderson JR; Jennings LJ; Green DM; Dome JS; Shamberger RC; Ruteshouser EC; Huff V
    J Clin Oncol; 2011 Feb; 29(6):698-703. PubMed ID: 21189373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK; Brown KW; Berry PJ
    Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
    Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
    Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
    Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
    Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
    Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
    Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
    Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
    Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
    Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
    Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
    Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.
    Sigamani E; Wari MN; Iyer VK; Agarwala S; Sharma A; Bakhshi S; Dinda A
    Pediatr Surg Int; 2013 Mar; 29(3):223-7. PubMed ID: 23292539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of WT1 and WIT1 genes and loss of heterozygosity on chromosome 11p in Wilms tumors in Japan.
    Kaneko Y; Takeda O; Homma C; Maseki N; Miyoshi H; Tsunematsu Y; Williams BG; Saunders GF; Sakurai M
    Jpn J Cancer Res; 1993 Jun; 84(6):616-24. PubMed ID: 8393432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
    Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
    J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
    Fawzy M; Bahanassy A; Samir A; Hafez H
    Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms' tumors in Japan.
    Nakadate H; Yokomori K; Watanabe N; Tsuchiya T; Namiki T; Kobayshi H; Suita S; Tsunematsu Y; Horikoshi Y; Hatae Y; Endo M; Komada Y; Eguchi H; Toyoda Y; Kikuta A; Kobayashi R; Kaneko Y
    Int J Cancer; 2001 Nov; 94(3):396-400. PubMed ID: 11745420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.